JP2021532148A5 - - Google Patents
Info
- Publication number
- JP2021532148A5 JP2021532148A5 JP2021504360A JP2021504360A JP2021532148A5 JP 2021532148 A5 JP2021532148 A5 JP 2021532148A5 JP 2021504360 A JP2021504360 A JP 2021504360A JP 2021504360 A JP2021504360 A JP 2021504360A JP 2021532148 A5 JP2021532148 A5 JP 2021532148A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- disease
- derivative
- approximately
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024087006A JP2024119868A (ja) | 2018-07-21 | 2024-05-29 | 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701726P | 2018-07-21 | 2018-07-21 | |
| US62/701,726 | 2018-07-21 | ||
| PCT/US2019/042827 WO2020023391A1 (en) | 2018-07-21 | 2019-07-22 | Enantiomerically purified gper agonist for use in treating disease states and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087006A Division JP2024119868A (ja) | 2018-07-21 | 2024-05-29 | 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532148A JP2021532148A (ja) | 2021-11-25 |
| JP2021532148A5 true JP2021532148A5 (https=) | 2022-07-29 |
| JPWO2020023391A5 JPWO2020023391A5 (https=) | 2022-07-29 |
Family
ID=69160978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504360A Pending JP2021532148A (ja) | 2018-07-21 | 2019-07-22 | 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト |
| JP2024087006A Pending JP2024119868A (ja) | 2018-07-21 | 2024-05-29 | 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024087006A Pending JP2024119868A (ja) | 2018-07-21 | 2024-05-29 | 病態および状態の処置に使用するための、エナンチオマー的に精製されたｇｐｅｒアゴニスト |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20200024262A1 (https=) |
| EP (2) | EP3823617B1 (https=) |
| JP (2) | JP2021532148A (https=) |
| KR (1) | KR20210049778A (https=) |
| CN (1) | CN112469409B (https=) |
| AU (1) | AU2019310029B2 (https=) |
| BR (1) | BR112021001031A2 (https=) |
| CA (1) | CA3107109A1 (https=) |
| DK (1) | DK3823617T3 (https=) |
| ES (1) | ES2980434T3 (https=) |
| FI (1) | FI3823617T3 (https=) |
| HR (1) | HRP20240661T1 (https=) |
| HU (1) | HUE067185T2 (https=) |
| IL (2) | IL312938A (https=) |
| LT (1) | LT3823617T (https=) |
| MX (2) | MX2021000809A (https=) |
| NZ (1) | NZ771952A (https=) |
| PL (1) | PL3823617T3 (https=) |
| PT (1) | PT3823617T (https=) |
| RS (1) | RS65599B1 (https=) |
| SI (1) | SI3823617T1 (https=) |
| SM (1) | SMT202400205T1 (https=) |
| WO (1) | WO2020023391A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022091029A1 (en) * | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| US20240376547A1 (en) * | 2021-04-08 | 2024-11-14 | Linnaeus Therapeutics, Inc. | Oncologic variations associated with cancer and methods of treatment |
| WO2022245899A2 (en) * | 2021-05-19 | 2022-11-24 | Linaeus Therapeutics, Inc. | Diagnostic methods and compositions for treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US251870A (en) * | 1882-01-03 | Automatic gate | ||
| US6809104B2 (en) * | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
| US7875721B2 (en) * | 2005-08-04 | 2011-01-25 | Stc.Unm | Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof |
| WO2008153945A2 (en) * | 2007-06-06 | 2008-12-18 | University Of South Florida | Nutraceutical co-crystal compositions |
| MX382354B (es) * | 2010-11-01 | 2025-03-13 | Celgene Car Llc | Compuestos heterocíclicos y usos de los mismos. |
| US10251870B2 (en) * | 2015-03-06 | 2019-04-09 | Stc.Unm | Method for treating obesity, diabetes, cardiovascular and kidney diseases by regulating GPR30/GPER activity |
| AU2016246688B2 (en) * | 2015-04-06 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject |
| US11369618B2 (en) | 2016-06-17 | 2022-06-28 | The Trustees Of The University Of Pennsylvania | Compounds, compositions and methods for prevention and/or treatment of cancer |
-
2019
- 2019-07-22 ES ES19842049T patent/ES2980434T3/es active Active
- 2019-07-22 BR BR112021001031-9A patent/BR112021001031A2/pt unknown
- 2019-07-22 US US16/518,516 patent/US20200024262A1/en not_active Abandoned
- 2019-07-22 IL IL312938A patent/IL312938A/en unknown
- 2019-07-22 PT PT198420499T patent/PT3823617T/pt unknown
- 2019-07-22 HU HUE19842049A patent/HUE067185T2/hu unknown
- 2019-07-22 JP JP2021504360A patent/JP2021532148A/ja active Pending
- 2019-07-22 PL PL19842049.9T patent/PL3823617T3/pl unknown
- 2019-07-22 SM SM20240205T patent/SMT202400205T1/it unknown
- 2019-07-22 AU AU2019310029A patent/AU2019310029B2/en active Active
- 2019-07-22 CA CA3107109A patent/CA3107109A1/en active Pending
- 2019-07-22 EP EP19842049.9A patent/EP3823617B1/en active Active
- 2019-07-22 FI FIEP19842049.9T patent/FI3823617T3/fi active
- 2019-07-22 RS RS20240634A patent/RS65599B1/sr unknown
- 2019-07-22 NZ NZ771952A patent/NZ771952A/en unknown
- 2019-07-22 WO PCT/US2019/042827 patent/WO2020023391A1/en not_active Ceased
- 2019-07-22 CN CN201980048925.4A patent/CN112469409B/zh active Active
- 2019-07-22 LT LTEPPCT/US2019/042827T patent/LT3823617T/lt unknown
- 2019-07-22 EP EP24161261.3A patent/EP4356913A3/en not_active Withdrawn
- 2019-07-22 KR KR1020217002117A patent/KR20210049778A/ko not_active Ceased
- 2019-07-22 DK DK19842049.9T patent/DK3823617T3/da active
- 2019-07-22 SI SI201930756T patent/SI3823617T1/sl unknown
- 2019-07-22 HR HRP20240661TT patent/HRP20240661T1/hr unknown
- 2019-07-22 IL IL280283A patent/IL280283B2/en unknown
- 2019-07-22 MX MX2021000809A patent/MX2021000809A/es unknown
- 2019-11-13 US US16/682,821 patent/US10934277B2/en active Active
-
2021
- 2021-01-20 MX MX2024008188A patent/MX2024008188A/es unknown
- 2021-02-25 US US17/184,870 patent/US11760749B2/en active Active
- 2021-05-24 US US17/328,590 patent/US20220089576A1/en not_active Abandoned
-
2023
- 2023-08-03 US US18/364,690 patent/US20230382896A1/en not_active Abandoned
-
2024
- 2024-05-29 JP JP2024087006A patent/JP2024119868A/ja active Pending
- 2024-06-24 US US18/752,146 patent/US20250171421A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102744039B1 (ko) | 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 | |
| CN104981458B (zh) | 组蛋白去甲基化酶抑制剂 | |
| CN113354653B (zh) | 二芳基大环多晶型物及其制备方法 | |
| JP2021532148A5 (https=) | ||
| CN103339139A (zh) | 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法 | |
| CN117659051A (zh) | Kras g12d蛋白抑制剂和其用途 | |
| JP6836693B2 (ja) | Ａ２ａ受容体アンタゴニストとしての縮合環誘導体 | |
| HRP20240661T1 (hr) | Enantiomerno pročišćeni agonist gper za upotrebu u liječenju bolesti stanja i bolesnih stanja | |
| TW202416964A (zh) | 製備激酶抑制劑之方法 | |
| KR102588109B1 (ko) | 암 치료에 유용한 1-(사이클로) 알킬 피리딘-2-온의 트리사이클릭 융합 유도체 | |
| JP2023544173A (ja) | 転写活性化タンパク質のイミダゾピペラジン阻害剤 | |
| EP3397641A1 (en) | 2h-chromeno[2,3-d]pyrimidine-2,4(3h)-diones as nf-kb inhibitors | |
| CA2914282A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor antagonists | |
| JPWO2020023391A5 (https=) | ||
| AU2021232072A1 (en) | STAT inhibitory compounds and compositions | |
| JP2023544732A (ja) | 転写活性化タンパク質のイミダゾピペラジン阻害剤 | |
| WO2006018955A1 (ja) | イソインドール誘導体の製造方法 | |
| CN116655497B (zh) | 脒类衍生化合物及其制备方法和用途 | |
| TW201938154A (zh) | 具有抗疼痛活性之鄰苯氧基及鄰苄氧基丙胺基衍生物 | |
| CN116589464B (zh) | 嘧啶并环类化合物、其制备方法和应用 | |
| TW202120095A (zh) | 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物 | |
| WO2021178841A1 (en) | Heterocycle containing stat inhibitors and compositions | |
| WO2021178857A1 (en) | Alpha substituted stat inhibitors and compositions thereof | |
| CN117285455A (zh) | 2-苯甲酰基吲哚类化合物及其应用 | |
| WO2018007957A1 (en) | Novel thiazolo[5,4-d]pyrimidine derivatives as inverse agonists of a2a adenosine receptors |